Moderna, Merck Melanoma Vaccine May Help Reduce Recurrence, Spread
A personalized mRNA melanoma vaccine developed by Moderna and Merck shows promise in reducing recurrence and spread. Iparraguirre Recio · Moment/Getty A late-stage trial found that a personalized mRNA therapy for melanoma outperformed Keytruda alone on two important measures of treatment success. The experimental treatment is tailored to the unique mutations in each patient’s tumor to help the…
Moderna and Merck's personalized mRNA melanoma vaccine, called intismeran, has shown promising results in a recent phase 3 trial. The vaccine, tailored to each patient's unique tumor mutations, is designed to help the immune system recognize and attack cancer cells. When combined with Keytruda (pembrolizumab), the trial met two key endpoints: recurrence-free survival and distant metastasis-free survival.
These results indicate that the combination treatment can reduce the risk of melanoma recurrence or death compared to Keytruda alone. However, detailed efficacy and safety results from the phase 3 trial have not been released yet. Experts believe the findings are encouraging, but further data is needed to fully understand the potential benefits and safety of this personalized treatment approach.
Written by urgent.news from Healthline News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
